Clinical Trial Update: Prospective, Multicenter, Open Label and Single-arm Study of Darbepoetin Alfa for Anemia in Myelodisplastic Syndrome Patients. [Phase 2]

View source ↗

Summary

A Phase 2, multicenter, open-label, single-arm trial evaluating darbepoetin alfa for anemia in myelodysplastic syndromes has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• darbepoetin alfa (darbepoetin alfa)

Snippet

Sponsor: Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon | Conditions: Myelodysplastic Syndrome | Phase 2 | Status: TERMINATED